Metabolic Research

Mazdutide

Not FDA approvedWeight & metabolic
5.6/10

BioHarmony verdict

Neutral

Mazdutide (IBI362) is the first GLP-1 plus glucagon dual agonist approved anywhere, cleared in China for obesity in June 2025. Its Phase 3 GLORY-1 trial showed about 14.84 percent weight loss at 48 weeks and roughly 72 to 80 percent liver fat reduction, the strongest published incretin liver signal.

Read full report

What is Mazdutide?

Mazdutide, also called IBI362 or LY3305677, is the first GLP-1 plus glucagon dual agonist to win regulatory approval anywhere in the world. China's National Medical Products Administration cleared it for obesity in mid-2025 and for type 2 diabetes a few months later, sold there under the brand name Xinermei, per Lee 2025. It is a once-weekly subcutaneous injection. What sets it apart from semaglutide and tirzepatide is the second receptor: alongside the familiar GLP-1 leg that suppresses appetite, mazdutide also switches on the glucagon receptor, which raises energy expenditure and pushes the liver to burn its own fat.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Activates both the GLP-1 receptor and the glucagon receptor, the second leg adding energy expenditure and hepatic fat clearance

Safety watch-outs

  • A persistent rise in resting heart rate, especially with palpitations: reduce the dose or stop and consult a clinician.
  • Severe or unrelenting upper abdominal pain that may radiate to the back (possible pancreatitis): stop immediately and seek care.
  • A neck lump, hoarseness, or trouble swallowing (the class thyroid warning): stop and get evaluated.
  • Any active or suspected medullary thyroid cancer, or a family history of it: do not use.
  • Signs of low blood sugar when combined with insulin or a sulfonylurea: stop the other drug or this one and consult a clinician.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for Mazdutide yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

US approvalNot FDA approved
CompoundingNo FDA-approved product; U.S. compounding eligibility is not established
Last checked2026-09-02
Next review2026-10-02 (overdue, details paused)

Primary sources

Sources are still being reviewed for this compound.

  1. 6.5/10MOTS-cWorth tryingWeight & metabolicNot FDA approvedMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
  2. 6.2/10IpamorelinWorth tryingRecoveryNot FDA approvedIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
  3. 6.1/10TirzepatideWorth tryingWeight & metabolicFDA-approved product existsTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
  4. 6.0/10Semaglutide (GLP-1 Agonist)Worth tryingWeight & metabolicFDA-approved product existsSemaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 6.0-6.5/10 score holds…

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.